Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 10 » Issue 1

Erdosteine reduces inflammation and time to first exacerbation postdischarge in hospitalized patients with AECOPD

Authors Moretti M, Fagnani S

Received 21 April 2015

Accepted for publication 6 July 2015

Published 28 October 2015 Volume 2015:10(1) Pages 2319—2325

DOI https://doi.org/10.2147/COPD.S87091

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Professor Hsiao-Chi Chuang

Peer reviewer comments 3

Editor who approved publication: Dr Richard Russell

Maurizio Moretti,1 Stefano Fagnani2

1Respiratory Unit, Massa-Carrara Hospital and University of Pisa, Pisa, Italy; 2Medical Department, Edmond Pharma Srl, Paderno Dugnano, Milan, Italy

Purpose: Mucolytics can improve disease outcome in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD). The objectives of this study were to investigate the effects of erdosteine (ER), a mucolytic agent with antioxidant activity, on systemic inflammation, symptoms, recurrence of exacerbation, and time to first exacerbation postdischarge in hospitalized patients with AECOPD.
Patients and methods: Patients admitted to hospital with AECOPD were randomized to receive either ER 900 mg daily (n=20) or a matching control (n=20). Treatment was continued for 10 days until discharge. Patients also received standard treatment with steroids, nebulized bronchodilators, and antibiotics as appropriate. Serum C-reactive protein levels, lung function, and breathlessness–cough–sputum scale were measured on hospital admission and thereafter at days 10 and 30 posttreatment. Recurrence of AECOPD-requiring antibiotics and/or oral steroids and time to first exacerbation in the 2 months (days 30 and 60) postdischarge were also assessed.
Results: Mean serum C-reactive protein levels were lower in both groups at days 10 and 30, compared with those on admission, with significantly lower levels in the ER group at day 10. Improvements in symptom score and forced expiratory volume in 1 second were greater in the ER than the control group, which reached statistical significance on day 10. ER was associated with a 39% lower risk of exacerbations and a significant delay in time to first exacerbation (log-rank test P=0.009 and 0.075 at days 30 and 60, respectively) compared with controls.
Conclusion: Results confirm that the addition of ER (900 mg/d) to standard treatment improves outcomes in patients with AECOPD. ER significantly reduced airway inflammation, improved the symptoms of AECOPD, and prolonged time to first exacerbation. The authors suggest ER could be most beneficial in patients with recurring, prolonged, and/or severe exacerbations of COPD.

Keywords: C-reactive protein, mucolytics, time to exacerbation, inflammation, COPD

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Switching treatments in COPD: implications for costs and treatment adherence

Braido F, Lavorini F, Blasi F, Baiardini I, Canonica GW

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2601-2608

Published Date: 3 December 2015

COPD in Taiwan: a National Epidemiology Survey

Cheng SL, Chan MC, Wang CC, Lin CH, Wang HC, Hsu JY, Hang LW, Chang CJ, Perng DW, Yu CJ

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2459-2467

Published Date: 11 November 2015

Pulmonary hemodynamic profile in chronic obstructive pulmonary disease [Corrigendum]

Portillo K, Torralba Y, Blanco I, Burgos F, Rodriguez-Roisin R, Rios J, Roca J, Barberà JA

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2377-2378

Published Date: 4 November 2015

Prevalence of chronic obstructive pulmonary disease in asymptomatic smokers

Sansores RH, Velázquez-Uncal M, Pérez-Bautista O, Villalba-Caloca J, Falfán-Valencia R, Ramírez-Venegas A

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2357-2363

Published Date: 2 November 2015

Effect of tiotropium on lung function decline in early-stage of chronic obstructive pulmonary disease patients: propensity score-matched analysis of real-world data

Lee HY, Choi SM, Lee J, Park YS, Lee CH, Kim DK, Lee SM, Yoon HI, Yim JJ, Kim YW, Han SK, Yoo CG

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2185-2192

Published Date: 13 October 2015

Enhancement of encapsulation efficiency of nanoemulsion-containing aripiprazole for the treatment of schizophrenia using mixture experimental design

Fard Masoumi HR, Basri M, Sarah Samiun W, Izadiyan Z, Lim CJ

International Journal of Nanomedicine 2015, 10:6469-6476

Published Date: 13 October 2015

Biomarker-based detection of asthma–COPD overlap syndrome in COPD populations

Tamada T, Sugiura H, Takahashi T, Matsunaga K, Kimura K, Katsumata U, Takekoshi D, Kikuchi T, Ohta K, Ichinose M

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2169-2176

Published Date: 9 October 2015

Endoscopic bronchial valve treatment: patient selection and special considerations

Eberhardt R, Gompelmann D, Herth FJF, Schuhmann M

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2147-2157

Published Date: 8 October 2015

Development, characterization, and skin delivery studies of related ultradeformable vesicles: transfersomes, ethosomes, and transethosomes

Ascenso A, Raposo S, Batista C, Cardoso P, Mendes T, Praça FG, Bentley MVLB, Simões S

International Journal of Nanomedicine 2015, 10:5837-5851

Published Date: 18 September 2015

Systemic signs of neutrophil mobilization during clinically stable periods and during exacerbations in smokers with obstructive pulmonary disease

Andelid K, Andersson A, Yoshihara S, Åhrén C, Jirholt P, Ekberg-Jansson A, Lindén A

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1253-1263

Published Date: 30 June 2015